BioSpace News Archive

Illumina, Inc. announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina’s current and future high throughput next-generation sequencing platforms.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO will participate in a virtual Fireside Chat during the 40th Annual J.P. Morgan Healthcare Conference.

ICON plc, a world-leading clinical research organisation powered by healthcare intelligence, announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual JP Morgan Healthcare Conference on Wednesday, January 12, 2022 at 07.30am ET.

NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the “Company”), today announced that the first patient has been enrolled in NANORAY-312, a global, open-label, two-arm, randomized, Investigator’s Choice phase III registration study that is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3.

Hepion Pharmaceuticals, Inc. announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.

Helios Cardio Inc. announces the Food and Drug Administration (FDA) 510(k) clearance for commercial distribution of CardiaMend™ Pericardial and Epicardial Reconstruction Matrix.

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today provided a clinical update from the Company’s ongoing, fully enrolled, dose-expansion Phase 1 study of STRO-002.

Bionomics Limited, a clinical-stage biopharmaceutical company, announced the issuance of 243,300 American Depositary Shares, each representing 180 ordinary shares of Bionomics, pursuant to the exercise in full of the underwriters’ option to purchase additional ADSs in connection with the Company’s previously announced initial public offering in the United States.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced its participation in and presentation at the 40th Annual J.P. Morgan Healthcare Conference.